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Aim. To investigate early outcomes after balloon aortic valve valvuloplasty (BAV) performed as pallia-
tive procedure in patients with decompensated unstable end-stage aortic stenosis (AS). 
Patients and Methods. A retrospective observational study was conducted in University Hospital Cen-
tre Zagreb. It included all patients who underwent lifesaving BAV, and had no options for surgical or 
transcatheter aortic valve replacement at the time, between 2015 and 2018. Clinical and echocardio-
graphic characteristics before and after BAV procedure were recorded.
Results. Study included 29 patients, mean age 80.2 (51-92) years, 65.5% women. Mean logistic Euroscore 
II was 24.1±21.1% and STS score 16.9±14.5%. Comorbidities included: coronary artery disease (48.28 %), 
diabetes mellitus (31.4 %), chronic renal insufficiency (58.6 %), peripheral artery disease (17.2 %) and 
atrial fibrillation (55.2 %). All patients were dependent on parenteral diuretics and 24.14 % on paren-
teral inotropic support. Echocardiographic parameter before and after BAV are presented in table 1. 
There was significant increase in indexed aortic valve area and decrease in pulmonary artery systolic 
pressure in overall population. There was no significant change in severity of aortic insufficiency. In-
hospital mortality was 20.1 % (N=6). Periprocedural complications included: 1 (3.4%) myocardial infarc-
tion, 1 (3.4%) major bleeding, 1 (3.4%) acute kidney injury and 2 (6.9%) vascular access complications. 
All other patients have been successfully weaned of parenteral therapy within 4 days and discharged.
Percutaneous and surgical interventions 
Extended Abstract 
Conclusion. BAV represents palliative treatment option in critically ill hemodynamically unstable 
patients with end-stage AS, who are not candidates for valve replacement.1 BAV provides clinical im-
provement due to increase AVA and decrease in PAPs, with acceptable mortality and complications 
rate.
tABLe 1. echocardiographic parameters before and after aortic valve balloon valvuloplasty.
Before BAV (n=29) After BAV (N=25) P value
Ejection fraction (%) 35.6±12.3 36.9±13.8 0.691
E/E´ 25.7±8.8 25.1±13.2 0.821
Maximal pressure gradient - mmHg 71.1±42.1 56.8±31.1 0.134
Mean pressure gradient – mmHg 41.7±24.1 31.1±14.9 0.055
Indexed aortic valve area 0.341±0.008 0.399±0.12 0.030
Any aortic insufficiency N (%) 22 (75.9) 21 (84) 0.459
More than mild mitral insufficiency N (%) 18 (62.1) 17 (68) 0.649
Pulmonary artery systolic pressure - mmHg 64.8±27.1 46.8±17.5 0.001
BAV = balloon aortic valve valvuloplasty
